CTLA4 and neoplasm: In general, patients with high TIDE scores are less likely to respond to immune checkpoint inhibitor (ICI) monotherapy (CTLA4 inhibitors or PD-1 inhibitors), and the predominance of high TIDE scores in the TNFSF9-high tumor suggests that ICI monotherapy may be less effective (Figure 5F,G).